Santhera Pharmaceuticals Holding (0QN1) Stock Statistics & Valuation Metrics
Total Valuation
Santhera Pharmaceuticals Holding has a market cap or net worth of CHF 234.69M. The enterprise value is CHF 271.86M.
- Market Cap
- CHF 234.69M
- Enterprise Value
- CHF 271.86M
Share Statistics
Santhera Pharmaceuticals Holding has 15,941,051 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 15,941,051
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Santhera Pharmaceuticals Holding’s return on equity (ROE) is 4.17 and return on invested capital (ROIC) is -37.53%.
- Return on Equity (ROE)
- 4.17
- Return on Assets (ROA)
- -0.33
- Return on Invested Capital (ROIC)
- -37.53%
- Return on Capital Employed (ROCE)
- -0.44
- Revenue Per Employee
- 989.55K
- Profits Per Employee
- -631.23K
- Employee Count
- 78
- Asset Turnover
- 0.52
- Inventory Turnover
- 2.52
Valuation Ratios
The current PE Ratio of Santhera Pharmaceuticals Holding is -6.72. Santhera Pharmaceuticals Holding’s PEG ratio is -0.08.
- PE Ratio
- -6.72
- PS Ratio
- 2.31
- PB Ratio
- -35.62
- Price to FCF
- 411.27
- Price to Operating Cash Flow
- 333.12
- PEG Ratio
- -0.08
Income Statement
In the last 12 months, Santhera Pharmaceuticals Holding had revenue of 77.19M and earned -49.24M in profits. Earnings per share was -3.78.
- Revenue
- 77.19M
- Gross Profit
- 14.47M
- Operating Income
- -37.82M
- Pretax Income
- -49.05M
- Net Income
- -49.24M
- EBITDA
- -32.13M
- Earnings Per Share (EPS)
- -3.78
Cash Flow
In the last 12 months, operating cash flow was 660.00K and capital expenditures -90,000, giving a free cash flow of 570.00K billion.
- Operating Cash Flow
- 660.00K
- Free Cash Flow
- 570.00K
- Free Cash Flow per Share
- 0.04
Dividends & Yields
Santhera Pharmaceuticals Holding pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 0.24%
- Earnings Yield
- -14.52%
Stock Price Statistics
- Beta
- 0.93
- 52-Week Price Change
- 49.30%
- 50-Day Moving Average
- 15.22
- 200-Day Moving Average
- 15.62
- Relative Strength Index (RSI)
- 53.74
- Average Volume (3m)
- 7,904
Important Dates
Santhera Pharmaceuticals Holding upcoming earnings date is Apr 29, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Sep 30, 2026
- Next Earnings Date
- Apr 29, 2027
- Ex-Dividend Date
- ―
Financial Position
Santhera Pharmaceuticals Holding as a current ratio of 1.29, with Debt / Equity ratio of -827.40%
- Current Ratio
- 1.29
- Quick Ratio
- 0.89
- Debt to Market Cap
- 0.53
- Net Debt to EBITDA
- -2.34
- Interest Coverage Ratio
- -3.27
Taxes
In the past 12 months, Santhera Pharmaceuticals Holding has paid 185.00K in taxes.
- Income Tax
- 185.00K
- Effective Tax Rate
- -0.00
Enterprise Valuation
Santhera Pharmaceuticals Holding EV to EBITDA ratio is -69.64, with an EV/FCF ratio of 410.41.
- EV to Sales
- 2.30
- EV to EBITDA
- -69.64
- EV to Free Cash Flow
- 410.41
- EV to Operating Cash Flow
- 354.44
Balance Sheet
Santhera Pharmaceuticals Holding has CHF 41.77M in cash and marketable securities with CHF 41.27M in debt, giving a net cash position of CHF 494.00K billion.
- Cash & Marketable Securities
- CHF 41.77M
- Total Debt
- CHF 41.27M
- Net Cash
- CHF 494.00K
- Net Cash Per Share
- CHF 0.03
- Tangible Book Value Per Share
- -CHF 4.71
Margins
Gross margin is 40.26%, with operating margin of -8.93%, and net profit margin of -31.46%.
- Gross Margin
- 40.26%
- Operating Margin
- -8.93%
- Pretax Margin
- -31.32%
- Net Profit Margin
- -31.46%
- EBITDA Margin
- -3.31%
- EBIT Margin
- -8.93%
Analyst Forecast
The average price target for Santhera Pharmaceuticals Holding is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 107.08%
- EPS Growth Forecast
- 55.54%